To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Departmental Publication (Transparency)
Ministry of Defence

Mar. 19 2024

Source Page: FOI responses published by MOD: week commencing 18 March 2024
Document: Joining the Royal Navy with spinal surgery for Scheuremann's disease (JSP 950) (PDF)

Found: homozygous or double heterozygous sickle cell disease, hereditary spherocytosis, homozygous α or β thalassaemia


Non-Departmental Publication (Statistics)
NHS England

Mar. 14 2024

Source Page: Q2 (1 July to 30 September 2023) ANNB and YPA screening KPI data
Document: (ODS)

Found: screening - coverage ST2 - Antenatal sickle cell and thalassaemia screening - timeliness of antenatal


Non-Departmental Publication (Statistics)
NHS England

Mar. 14 2024

Source Page: Q1 (1 April to 30 June 2023) ANNB and YPA screening KPI data
Document: (ODS)

Found: screening - coverage ST2 - Antenatal sickle cell and thalassaemia screening - timeliness of antenatal


Commons Chamber
Business of the House - Thu 07 Mar 2024
Leader of the House

Mentions:
1: Bell Ribeiro-Addy (Lab - Streatham) landmark report by the Sickle Cell Society and the all-party parliamentary group on sickle cell and thalassaemia - Speech Link


Written Question
Blood Diseases: Medical Treatments
Wednesday 21st February 2024

Asked by: George Howarth (Labour - Knowsley)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) NICE and (b) NHS England on encouraging the adoption of new treatments for (i) sickle cell disease and (ii) beta-thalassaemia.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department regularly discusses a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), related to patient access to new treatments.

The NICE appraises all new licensed medicines, and its recommendations are developed independently in line with its established methods and processes, on the basis of an assessment of the available evidence, and through extensive engagement with stakeholders. NHS England is legally required to fund treatments recommended in NICE technology appraisal guidance.


Written Question
Pakistan: Thalassaemia
Tuesday 20th February 2024

Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)

Question to the Foreign, Commonwealth & Development Office:

To ask His Majesty's Government what representations they have made to the government of Pakistan on ensuring the availability of thalassaemia treatment and awareness; and what allocations of the Official Development Aid is being put towards this.

Answered by Lord Ahmad of Wimbledon - Minister of State (Foreign, Commonwealth and Development Office)

The UK uses Official Development Assistance (ODA) to support Pakistan in realising its ambition of Universal Health Coverage (UHC) and ending preventable deaths of mothers, babies and children. We take a systems approach to this, providing technical assistance to strengthen decision making on health policy and financing. We also build the evidence base on effective sub-system interventions for UHC. No specific investments are made in Thalassaemia treatment or awareness raising in Pakistan. However, our support will strengthen core components of Pakistan's health system and increase coverage and service offers that should be of benefit to those with Thalassaemia.


Non-Departmental Publication (Statistics)
Office for Health Improvement and Disparities

Feb. 06 2024

Source Page: Public Health Outcomes Framework: February 2024 data update
Document: Public Health Outcomes Framework: indicator updates, 6 February 2024 (PDF)

Found: Updated England Region No additional breakdown All ages Yes OHID C24k - Sickle Cell and Thalassaemia


Commons Chamber
Oral Answers to Questions - Tue 23 Jan 2024
Department of Health and Social Care

Mentions:
1: Andrew Stephenson (Con - Pendle) Lady in her role as chair of the sickle cell and thalassaemia all-party parliamentary group. - Speech Link


Non-Departmental Publication (Statistics)
NHS England

Dec. 14 2023

Source Page: Q1 (1 April to 30 June 2023) ANNB and YPA screening KPI data
Document: (ODS)

Found: screening - coverage ST2 - Antenatal sickle cell and thalassaemia screening - timeliness of antenatal


Departmental Publication (Transparency)
Ministry of Defence

Dec. 06 2023

Source Page: FOI responses published by MOD: week commencing 4 December 2023
Document: Latest version of JSP 950 (PDF)

Found: homozygous or double heterozygous sickle cell disease, hereditary spherocytosis, homozygous α or β thalassaemia